HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fernández-Real, J. M. Articles by Ricart, W. Search for Related Content PubMed PubMed Citation Articles by Fernández-Real, J. M. Articles by Ricart, W. Social Bookmarking                What's this?

Blood Letting in High-Ferritin Type 2 Diabetes

Effects on Insulin Sensitivity and ß-Cell Function

¹ Unit of Diabetes, Endocrinology and Nutrition, University Hospital of Girona "Dr. Josep Trueta," Girona, Spain
² Department of Internal Medicine, University Hospital of Girona "Dr. Josep Trueta," Girona, Spain
³ Division of Preventive Medicine and Public Health, University "Miguel Hernández," Alicante, Spain

Iron-related insulin-resistance is improved by iron depletion or treatment with iron chelators. The aim of this study was to evaluate insulin sensitivity and insulin secretion after blood letting in patients who had high-ferritin type 2 diabetes and were randomized to blood letting (three phlebotomies [500 ml of blood] at 2-week intervals, group 1) or to observation (group 2). Insulin secretion and sensitivity were tested at baseline and 4 and 12 months thereafter. The two groups were matched for age, BMI, pharmacologic treatment, and chronic diabetic complications. All patients were negative for C282Y mutation of hereditary hemochromatosis. Baseline glycated hemoglobin (6.27 ± 0.9% vs. 6.39 ± 1.2%), insulin sensitivity (2.75 ± 1.8 vs. 3.2 ± 2.1 mg · dl^-1 · min^-1), and area under the curve for C-peptide (AUC_C-peptide; 38.7 ± 11.6 vs. 37.6 ± 14.1 ng · ml^-1 · min^-1) were not significantly different between the two groups of patients. Body weight, blood pressure, blood hematocrit levels, and drug treatment remained essentially unchanged during the study period. As expected, serum ferritin, transferrin saturation index, and blood hemoglobin decreased significantly at 4 months only in patients who received blood letting. In parallel to this changes, blood HbA_1c decreased significantly only in group 1 subjects (mean differences, -0.61; 95% CI, -0.17 to -1.048; P = 0.01). AUC_C-peptide decreased by -10.2 ± 6.3% after blood letting. In contrast, a 10.4 ± 6.4% increase in AUC_C-peptide was noted in group 2 subjects at 4 months (P = 0.032). At 12 months, AUC_C-peptide returned to values not significantly different from baseline in the two groups of subjects. At 4 months, the change in insulin sensitivity from baseline was significantly different between the two groups (80.6 ± 43.2% vs. -8.6 ± 9.9% in groups 1 and 2, respectively, P = 0.049). At 12 months, the differences between the two groups were even more marked (55.5 ± 24.8% vs. -26.8 ± 9.9%; P = 0.005). When the analysis was restricted to those subjects who completed the follow-up until 12 months, results did not show differences compared with the changes observed at 4 months, except for insulin sensitivity. A statistically significant increase in insulin sensitivity was observed in the blood-letting group (from 2.30 ± 1.81 to 3.08 ± 2.55 mg · dl^-1 · min^-1 at 4 months, to 3.16 ± 1.85 mg · dl^-1 · min^-1 at 12 months; P = 0,045) in contrast with group 2 subjects (from 3.24 ± 1.9 to 3.26 ± 2.05 mg · dl^-1 · min^-1 at 4 months, to 2.31 ± 1.35 mg · dl^-1 · min^-1 at 12 months). In summary, blood letting led simultaneously to decreased blood HbA_1c levels and to changes in insulin secretion and insulin resistance that were significantly different from those observed in a matched observational group of subjects with high-ferritin type 2 diabetes. The mechanisms for improvement in peripheral insulin sensitivity after blood letting should be investigated further.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. M. Fernandez-Real, J. M. Moreno, and W. Ricart Circulating Retinol-Binding Protein-4 Concentration Might Reflect Insulin Resistance-Associated Iron Overload Diabetes, July 1, 2008; 57(7): 1918 - 1925. [Abstract] [Full Text] [PDF]

				S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF]

				A. Lopez-Bermejo, J. Khosravi, W. Ricart, A. Castro, V. Hwa, K. L. Pratt, R. Casamitjana, R. G. Rosenfeld, and J. M. Fernandez-Real Insulin-Like Growth Factor Binding Protein-Related Protein 1 (IGFBP-rP1/MAC25) Is Linked to Endothelial-Dependent Vasodilation in High-Ferritin Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1615 - 1617. [Full Text] [PDF]

				L. Mascitelli, F. Pezzetta, and J. L. Sullivan Inhibition of Iron Absorption by Coffee and the Reduced Risk of Type 2 Diabetes Mellitus Arch Intern Med, January 22, 2007; 167(2): 204 - 205. [Full Text] [PDF]

				L. Mascitelli and F. Pezzetta Green tea, coffee, and diabetes. Ann Intern Med, October 17, 2006; 145(8): 634 - 634. [Full Text] [PDF]

				F. Fumeron, F. Pean, F. Driss, B. Balkau, J. Tichet, M. Marre, B. Grandchamp, and for the DESIR Study Group Ferritin and Transferrin Are Both Predictive of the Onset of Hyperglycemia in Men and Women Over 3 Years: The Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care, September 1, 2006; 29(9): 2090 - 2094. [Abstract] [Full Text] [PDF]

				S. Rajpathak, J. Ma, J. Manson, W. C. Willett, and F. B. Hu Iron Intake and the Risk of Type 2 Diabetes in Women: A prospective cohort study. Diabetes Care, June 1, 2006; 29(6): 1370 - 1376. [Abstract] [Full Text] [PDF]

				D.-H. Lee, D. Y. Liu, D. R. Jacobs Jr., H.-R. Shin, K. Song, I.-K. Lee, B. Kim, and R. C. Hider Common Presence of Non-Transferrin-Bound Iron Among Patients With Type 2 Diabetes Diabetes Care, May 1, 2006; 29(5): 1090 - 1095. [Abstract] [Full Text] [PDF]

				C E Wrede, R Buettner, L C Bollheimer, J Scholmerich, K-D Palitzsch, and C Hellerbrand Association between serum ferritin and the insulin resistance syndrome in a representative population Eur. J. Endocrinol., February 1, 2006; 154(2): 333 - 340. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, and W. Ricart Iron Stores, Blood Donation, and Insulin Sensitivity and Secretion Clin. Chem., July 1, 2005; 51(7): 1201 - 1205. [Abstract] [Full Text] [PDF]

				A. Lecube, C. Hernandez, J. Genesca, J. I. Esteban, R. Jardi, L. Garcia, and R. Simo Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection Diabetes Care, November 1, 2004; 27(11): 2669 - 2675. [Abstract] [Full Text] [PDF]

				M. Jehn, J. M. Clark, and E. Guallar Serum Ferritin and Risk of the Metabolic Syndrome in U.S. Adults Diabetes Care, October 1, 2004; 27(10): 2422 - 2428. [Abstract] [Full Text] [PDF]

				J. M. Rumberger, T. Peters Jr, C. Burrington, and A. Green Transferrin and Iron Contribute to the Lipolytic Effect of Serum in Isolated Adipocytes Diabetes, October 1, 2004; 53(10): 2535 - 2541. [Abstract] [Full Text] [PDF]

				S. Ghosh, S. Hevi, and S. L. Chuck Regulated secretion of glycosylated human ferritin from hepatocytes Blood, March 15, 2004; 103(6): 2369 - 2376. [Abstract] [Full Text] [PDF]

				F. S. Facchini Near-iron deficiency-induced remission of gouty arthritis Rheumatology, December 1, 2003; 42(12): 1550 - 1555. [Abstract] [Full Text] [PDF]

				M. Haap, A. Fritsche, H. J. Mensing, H.-U. Haring, and M. Stumvoll Association of High Serum Ferritin Concentration with Glucose Intolerance and Insulin Resistance in Healthy People Ann Intern Med, November 18, 2003; 139(10): 869 - 871. [Full Text] [PDF]

				L. R Zacharski and G. S Gerhard Perspective: Atherosclerosis: a manifestation of chronic iron toxicity? Vascular Medicine, August 1, 2003; 8(3): 153 - 155. [PDF]

				D. J. Halsall, I. McFarlane, J.'a. Luan, T. M. Cox, and N. J. Wareham Typical type 2 diabetes mellitus and HFE gene mutations: a population-based case - control study Hum. Mol. Genet., June 15, 2003; 12(12): 1361 - 1365. [Abstract] [Full Text] [PDF]

				F. S. Facchini and K. L. Saylor A Low-Iron-Available, Polyphenol-Enriched, Carbohydrate-Restricted Diet to Slow Progression of Diabetic Nephropathy Diabetes, May 1, 2003; 52(5): 1204 - 1209. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, M. Broch, C. Richart, J. Vendrell, A. Lopez-Bermejo, and W. Ricart CD14 Monocyte Receptor, Involved in the Inflammatory Cascade, and Insulin Sensitivity J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1780 - 1784. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, and W. Ricart Cross-Talk Between Iron Metabolism and Diabetes Diabetes, August 1, 2002; 51(8): 2348 - 2354. [Abstract] [Full Text] [PDF]